(Q33942357)

30 July 2017

1 reference

title

Lipid-lowering treatment in coronary artery disease: how low should cholesterol go? (English)

1 reference

30 July 2017

main subject

coronary artery disease

1 reference

Jones PH

1

1 reference

30 July 2017

publication date

1 May 2000

1 reference

30 July 2017

1 reference

30 July 2017

volume

59

1 reference

30 July 2017

issue

5

1 reference

30 July 2017

page(s)

1127-1135

1 reference

Assessing possible hazards of reducing serum cholesterol

30 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059050-00008

Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003495-200059050-00008

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

21 January 2018

1 reference

12 December 2020

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

12 December 2020

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

12 December 2020

Statin trials and goals of cholesterol-lowering therapy

1 reference

12 December 2020

Lipid-lowering interventions in angiographic trials

1 reference

12 December 2020

Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)

1 reference

12 December 2020

W.H.O. cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Report of the Committee of Principal Investigators

1 reference

12 December 2020

Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators

1 reference

12 December 2020

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 reference

12 December 2020

Cholesterol lowering and mortality: the importance of considering initial level of risk

1 reference

12 December 2020

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

1 reference

12 December 2020

National Cholesterol Education Program. Second Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

1 reference

12 December 2020

Clofibrate and niacin in coronary heart disease

1 reference

12 December 2020

Cerivastatin in primary hyperlipidemia: a multicenter analysis of efficacy and safety

1 reference

12 December 2020

Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials

1 reference

12 December 2020

The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts

1 reference

12 December 2020

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

12 December 2020

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS)

1 reference

12 December 2020

Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators.

1 reference

12 December 2020

Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events trial.

1 reference

12 December 2020

Report of the Conference on Low Blood Cholesterol: Mortality Associations

1 reference

12 December 2020

Serum cholesterol in young men and subsequent cardiovascular disease

1 reference

12 December 2020

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

12 December 2020

The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease

1 reference

12 December 2020

Efficacy and safety of simvastatin 80 mg/day in hypercholesterolemic patients. The Expanded Dose Simvastatin U.S. Study Group

1 reference

12 December 2020

Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations

1 reference

12 December 2020

Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT).

1 reference

12 December 2020

10.2165/00003495-200059050-00008

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

1030363093

0 references

1 reference